Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
La Revue Du Praticien|January 31, 2024
[Tyrosine kinase inhibitors for chronic myeloid leukemia]Delphine RéaCritical Reviews in Oncology/Hematology|January 12, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1Delphine Réa, Timothy P HughesBulletin Du Cancer|June 20, 2022
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia]Delphine Réa, Emmanuel Messas, Tristan Mirault, et al.Expert Review of Hematology|July 10, 2023
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemiaFrançoise Huguet, Delphine Réa, Emilie Cayssials, et al.Medecine Sciences : M/S|August 2, 2018
[NK cells: a major role in the antitumoral immunomodulation in CML]Antoine Toubert, Ali Turhan, Agnès Guerci-Bresler, et al.Leukemia|May 6, 2020
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitorsAndreas Hochhaus, Massimo Breccia, Giuseppe Saglio, et al.Clinical Biochemistry|June 11, 2014
Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scaleCarole Mauté, Olivier Nibourel, Delphine Réa, et al.Bulletin Du Cancer|September 4, 2025
[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia]Jean-Michel Cayuela, Stéphanie Dulucq, Sandrine Hayette, et al.Cellular Microbiology|January 27, 2007
Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cellsNicolas Dulphy, Jean-Louis Herrmann, Jérôme Nigou, et al.Journal of Cancer Research and Clinical Oncology|January 27, 2023
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitorsEhab Atallah, Michael J Mauro, Andreas Hochhaus, et al.Pageof 4